Compare FUN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUN | AGIO |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2023 | 2013 |
| Metric | FUN | AGIO |
|---|---|---|
| Price | $19.98 | $32.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $23.92 | ★ $39.88 |
| AVG Volume (30 Days) | ★ 1.6M | 952.6K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,100,289,000.00 | $43,011,000.00 |
| Revenue This Year | $4.76 | $74.95 |
| Revenue Next Year | $3.73 | $165.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.45 | N/A |
| 52 Week Low | $12.51 | $22.24 |
| 52 Week High | $38.27 | $46.00 |
| Indicator | FUN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 59.32 |
| Support Level | $14.85 | $26.64 |
| Resistance Level | $27.37 | $36.35 |
| Average True Range (ATR) | 0.96 | 1.46 |
| MACD | 0.29 | 0.24 |
| Stochastic Oscillator | 92.44 | 59.22 |
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS. The parks are family-oriented, with recreational facilities for people of all ages, and provide clean and attractive environments with exciting rides and immersive entertainment. The Company generates revenue from sales of admission to the amusement parks and water parks, from purchases of food, merchandise and games both inside and outside the parks, from the sale of accommodations and other extra-charge.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.